RecruitingRecruiting
iDose TR Administration in an Office-Based Surgery Setting
NCT07816692 · Glaukos Corporation
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting
About this study
This study is a multicenter, single arm, open-label trial in adult subjects with open-angle glaucoma or ocular hypertension. The objective of the study is to assess the safety profile of iDose TR administration in an office-based surgery setting.
Eligibility criteria
Inclusion Criteria:
* Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)
Exclusion Criteria:
* Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation
Study design
Enrollment target: 30 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-05-13
Estimated completion: 2027-03
Last updated: 2026-09-14
Interventions
Combination Product: iDose TR (travoprost intracameral implant) 75 µg
Primary outcomes
- • Successful administration of iDose TR in an office-based surgical setting. (3 months)
Sponsor
Glaukos Corporation · industry
Contacts & investigators
ContactStudy Director · contact · ClinicalResearch@glaukos.com · 949-739-8749
All locations (1)
Glaukos Investigative SiteRecruiting
Austin, Texas, United States